DuPont Pioneer has acquired the exclusive rights to ERS Genomics' portfolio of CRISPR-Cas genome-editing technologies for all plant and agricultural applications.
The company said its acquisition of DuPont Diagnostics will allow it to provide a broader array of food safety diagnostics services to its customers.
DuPont Pioneer has entered into a collaboration to apply CRISPR genome editing to the development of crop varieties for farmers in developing countries.
DuPont Pioneer researchers used a CRISPR genome editing approach to develop corn that appears to be more drought tolerant.
The firms also renewed distribution agreements for DuPont's BAX System Q7 food safety testing platform in Canada, Australia and New Zealand.
The in vitro assay enabled the scientists to take an uncharacterized Cas9 variant from Brevibacillus laterosporus and edit maize cells with it.
DuPont teams with genome editing firm Caribou Biosciences for agricultural applications of the technology.
The ag-bio giant and the CRISPR research tools company will cross-license patents and collaborate to further develop the genome editing toolkit.
The deal gives DuPont Pioneer exclusive rights to the technology for all commercial applications.
DuPont said the acquisition will boost its in-house microbial discovery programs.
Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.
US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.
A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.
In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.